This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaaks, R. Articles by Toniolo, P. Search for Related Content PubMed PubMed Citation Articles by Kaaks, R. Articles by Toniolo, P.

Correspondence re: Giovannucci et al., A Prospective Study of Plasma Insulin-like Growth Factor-1 and Binding Protein-3 and Risk of Colorectal Neoplasia in Women. Cancer Epidemiol. Biomark. Prev., 9: 345–349, 2000

International Agency for Research on Cancer, 69372 Lyon, Cedex 08, France [R. K., S. R., A. L.], and Department of Obstetrics and Gynecology [A. A., P. T.] and Department of Environmental Medicine [A. Z-J.], New York University, New York, New York 10016

Giovannucci et al. showed an increased risk of colorectal cancer in women with elevated prediagnostic blood levels of IGF-I,² but only when an adjustment was made for levels of IGFBP-3, IGF’s principal plasmatic binding protein. In other studies, by the same Harvard group, adjustment for IGFBP-3 also strengthened the association of IGF-I risk of colorectum and prostate cancer in men (1 , 2) . In univariate analyses, cancer risk was either unassociated or mildly reduced at elevated levels of IGFBP-3, but multivariate models systematically showed a significant inverse association of risk with IGFBP-3 adjusted for IGF-I. By contrast, in a different series of prospective studies, we systematically observed increases in risk of cancers of the colorectum³ (3) and prostate (4) in subjects with elevated IGFBP-3, and adjustment for IGFBP-3 reduced or even abolished the associations of risk with IGF-I levels.

We speculated that these discrepancies might be related to differences in the specificity of IGFBP-3 assays. In the Harvard studies, IGFBP-3 was measured by an ELISA method from Diagnostic Systems Laboratories (Webster, TX). In our studies, an IRMA from Immunotech (Marseilles, France) was used² (3 , 4) . IGFBP-3 in blood and tissues undergoes proteolytic cleavage by specific enzymes. We hypothesized that subjects at increased cancer risk might have elevated levels of IGFBP-3, intact and proteolytically cleaved forms combined, and our Immunotech assays would measure the sum of these. However, subjects at increased cancer risk might have reduced levels of intact (uncleaved) IGFBP-3, and the DSL-ELISA assay would be more specific for intact IGFBP-3.

To test this hypothesis, we remeasured IGFBP-3 by the DSL-ELISA method in our prospective study on colorectal cancer (3) . IGF-I had been measured by an assay from Immunotech, which uses acid-ethanol to precipitate the IGFBPs. IGFBP-3 levels for cases and controls were 3019.8 ± 587.6 and 2921.7 ± 575.3 ng/ml (mean ± SD), respectively, for IRMA-Immunotech and 4074.3 ± 938.6 and 3951.7 ± 778.8 ng/ml (mean ± SD), respectively, for ELISA-DSL. Spearman’s correlations between the two IGFBP-3 assays were 0.82. The odds ratio of colorectal cancer for the top quintile of IGFBP-3 was lower (1.24) for the DSL-ELISA measurement than for the measurements by Immunotech, somewhat in line with our speculation, but did not reflect a possible inverse association of risk with IGFBP-3 (Table 1) . Furthermore, with neither of the IGFBP-3 assays used was there any clear increase in risk for elevated IGF-I levels adjusted for IGFBP-3, nor was there any inverse association of risk with IGFBP-3 adjusting for IGF-I (data not shown).

Footnotes

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon, Cedex 08, France.

² The abbreviations used are: IGF, insulin-like growth factor; IGFBP, IGF-binding protein; IRMA, immunoradiometric assay; DSL, Diagnostic Systems Laboratories.

³ R. Palmqvist, G. Hallmans, S. Rinaldi, C. Biessy, R. Stenling, E. Riboli, and R. Kaaks. Plasma IGF-I, IGF-binding protein-3 and risk of colorectal cancer: a prospective study in Northern Sweden, Gut, in press, 2001.

Received 4/13/01; revised 6/15/01; accepted 7/27/01.

References

1. Ma J., Pollak M. N., Giovannucci E., Chan J. M., Tao Y., Hennekens C. H., Stampfer M. J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. (Bethesda), 91: 620-625, 1999.[Abstract/Free Full Text]
2. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Wash. DC)., 279: 563-566, 1998.[Abstract/Free Full Text]
3. Kaaks R., Toniolo P., Akhmedkhanov A., Lukanova A., Biessy C., Dechaud H., Rinaldi S., Zeleniuch-Jacquotte A., Shore R. E., Riboli E. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J. Natl. Cancer Inst. (Bethesda), 92: 1592-1600, 2000.[Abstract/Free Full Text]
4. Stattin P., Bylund A., Rinaldi S., Biessy C., Dechaud H., Stenman U. H., Egevad L., Riboli E., Hallmans G., Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. (Bethesda), 92: 1910-1917, 2000.[Abstract/Free Full Text]

This article has been cited by other articles:

				N. E. Allen, T. J. Key, P. N. Appleby, R. C. Travis, A. W. Roddam, S. Rinaldi, L. Egevad, S. Rohrmann, J. Linseisen, T. Pischon, et al. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1121 - 1127. [Abstract] [Full Text] [PDF]

				D. Berrigan, N. Potischman, K. W. Dodd, M. Nicar, G. McQuillan, J. A. Lavigne, J. C. Barrett, and R. Ballard-Barbash Serum Levels of Insulin-like Growth Factor-I and Insulin-like Growth Factor-I Binding Protein-3: Quality Control for Studies of Stored Serum Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1017 - 1022. [Abstract] [Full Text] [PDF]

				S. Rinaldi, R. Kaaks, A. Zeleniuch-Jacquotte, A. A. Arslan, R. E. Shore, K. L. Koenig, L. Dossus, E. Riboli, P. Stattin, A. Lukanova, et al. Insulin-Like Growth Factor-I, IGF Binding Protein-3, and Breast Cancer in Young Women: A Comparison of Risk Estimates Using Different Peptide Assays Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 48 - 52. [Abstract] [Full Text] [PDF]

				P. Stattin, S. Rinaldi, C. Biessy, U.-H. Stenman, G. Hallmans, and R. Kaaks High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort J. Clin. Oncol., August 1, 2004; 22(15): 3104 - 3112. [Abstract] [Full Text] [PDF]

				M. S. Sandhu, D. B. Dunger, and E. L. Giovannucci Insulin, Insulin-Like Growth Factor-I (IGF-I), IGF Binding Proteins, Their Biologic Interactions, and Colorectal Cancer J Natl Cancer Inst, July 3, 2002; 94(13): 972 - 980. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaaks, R. Articles by Toniolo, P. Search for Related Content PubMed PubMed Citation Articles by Kaaks, R. Articles by Toniolo, P.